Showing 1121-1130 of 1477 results for "".
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- Oculis Announces Positive Results from Phase 3 Trial of Once Daily Treatment for Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-announces-positive-results-from-phase-3-trial-of-once-daily-ocs-01-for-treatment-of-inflammation-and-pain-following-cataract-surgery/2482221/Oculis announced positive results from the phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS annual meeting in Boston. Eric Donnenfeld, MD, presented the “Once Daily OCS-01, an OPTIREACH F
- Adverum Announces Positive Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-preliminary-efficacy-and-safety-data-from-luna-phase-2-trial-of-ixo-vec-in-patients-with-wet-amd/2482107/Adverum Biotechnologies announced preliminary safety and efficacy data from the ongoing LUNA phase 2 trial in patients with wet age-related macular degeneration (AMD). These data are being presented by Arshad Khanani, MD, today at the 47th Annual Meeting of the Macula Society. The presentation, t
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- IntRIS Hosts ARCR Macular 2024 Meeting and Presents Interview With FDA’s Dr. Wiley Chambershttps://modernod.com/news/intris-hosts-arcr-macular-2024-meeting-and-presents-interview-with-fdas-dr-wiley-chambers/2482057/The International Retinal Imaging Society (IntRIS) hosted the Atlantic Coast Retina Club (ACRC) Macula 2024, led by K. Bailey Freund, MD. According IntRIS, the ACRC meeting format includes rapid-fire single-case presentations, engaging discussions, and conferences covering diverse retin
- New "Eye Chart" App Designed to Address Common Challenges in Near Vision Testinghttps://modernod.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/A new app aims to address common challenges encountered in near vision testing. The "Eye Chart" app, which was developed by Michael Ullman, MD, a cornea specialist at Ullman Eye Consultants in Pensacola, Florida, leverages the iPhone's TrueDepth camera to me
- Nanoscope Therapeutics Wins 'Best of Show' Award at AAO Eyecelerator 2023https://modernod.com/news/nanoscope-therapeutics-wins-best-of-show-award-at-aao-eyecelerator-2023/2481955/Nanoscope Therapeutics was awarded the 'Best of Show in Retina' award at this year's American Academy of Ophthalmology (AAO) Eyecelerator conference held in San Francisco on Thursday, November 2, 2023. During the conference, Samuel Barone, MD, Nanoscope's chief
- Lighthouse Guild Presents 2023 Awardshttps://modernod.com/news/lighthouse-guild-presents-2023-awards/2481905/Lighthouse Guild hosted its 2023 lecture and awards ceremony at its headquarters in New York on October 19. The awards recognize outstanding accomplishments in vision science, technological innovation, and advocacy. Wiley A. Chambers, MD, was awarded
- Phase 3 Stage 1 DIAMOND Trial Results of Oculis' OCS-01 in DME Presented at Euretinahttps://modernod.com/news/phase-3-stage-1-diamond-trial-results-of-oculis-ocs-01-in-dme-presented-euretina/2481877/Oculis announced that Professor Ramin Tadayoni, MD, PhD, presented the positive results from stage 1 of the phase 3 DIAMOND trial of OCS-01 in patients with DME at the 23rd EURETINA congress in Amsterdam. The data showed that the trial met primary and secondary endpoints
- Amber Ophthalmics Announces First Patient Enrolled in Phase 2/3 Trial Evaluating Nexagon for the Treatment of PCEDhttps://modernod.com/news/amber-ophthalmics-announces-first-patient-enrolled-in-phase-23-trial-evaluating-nexagon-for-the-treatment-of-pced/2481785/Amber Ophthalmics announced that Mark S. Gorovoy, MD, has enrolled the first patient in the AMB-01-006 (NEXPEDE-1), a randomized, double-masked, vehicle-controlled phase 2/3 clinical trial designed to evaluate two concentrations of Nexagon (lufepirsen ophthalmic gel) for